Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.…
Spyre Therapeutics to Participate in Upcoming Investor Conferences
Spyre Therapeutics (NASDAQ: SYRE) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 130 employees.
The shares were at 93.47 USD on 20 November 2026, up 317.5% over 52 weeks. Its 52-week range is 21.14 USD to 110.64 USD: the price is 15.5% below the high and 342.0% above the low.
Its market capitalisation is 8.88B USD.
Spyre Therapeutics reports return on equity of -21.7% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 1.07B USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 15 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 123.87 USD is 32.5% above the current price. The next earnings report is expected on 18 February 2027.